Emodin as a Circadian‑Sensitized Senolytic that Restores BMAL1 Stability via MAPK Inhibition

Hypothesis

Emodin selectively eliminates senescent cells that have arisen from circadian disruption by inhibiting MAPK signaling, which in turn stabilizes the BMAL1 protein and reinstates circadian transcriptional repression of senescence‑associated programs.

Rationale

Circadian loss‑of‑function (e.g., BMAL1 or CLOCK knockdown) hyperactivates MAPK/ERK pathways, driving p16^INK4a^/p21^CIP1^ expression and senescence [1]. Senescent cells that emerge under this condition become dependent on sustained MAPK signaling for survival [2]. Emodin is a potent inhibitor of EGFR‑mediated MAPK/ERK signaling [3] and can induce apoptosis via caspase‑3 activation [4]; however, its selectivity for senescent versus proliferating cells remains untested. Notably, ERK‑mediated phosphorylation of BMAL1 targets it for proteasomal degradation [5]; thus, MAPK inhibition by emodin could prevent BMAL1 turnover, enhancing its nuclear accumulation and transcriptional activity. Restored BMAL1 would then repress AP‑1‑driven senescence effectors and re‑establish circadian gating of autophagy and DNA‑damage response, creating a dual senolytic/circadian‑restorative mechanism.

Predictions

1. In cells with circadian disruption (e.g., Bmal1 siRNA or chronic jet‑lag regimen), emodin will reduce viability more strongly than in circadian‑intact controls.
2. This selective toxicity will correlate with decreased phospho‑ERK, increased total BMAL1 protein, and diminished p16/p21 and SASP IL‑6/IL‑8 levels.
3. Rescue experiments overexpressing a non‑degradable BMAL1 mutant will blunt emodin‑induced senescence clearance, whereas BMAL1 knockdown will sensitize cells to emodin even without prior circadian disruption.
4. Emodin treatment will increase circadian rhythm amplitude (measured by PER2::luciferase bioluminescence) in previously arrhythmic senescent cultures.

Experimental Design

• Cell models: Human IMR‑90 fibroblasts and WI‑38 lung fibroblasts; induce senescence via ionizing radiation (10 Gy) or replicative exhaustion. Parallel sets receive Bmal1 siRNA or are cultured under simulated shift‑work (8‑hour light/dark shifts) to disrupt the clock.
• Treatment: Emodin (0‑50 µM, 24 h) ± ERK inhibitor (U0126) as positive control; vehicle (DMSO) controls.
• Readouts: Cell viability (CellTiter‑Glo), senescence markers (β‑galactosidase, p16/p21 Western blot), SASP cytokines (ELISA for IL‑6, IL‑8), MAPK activity (phospho‑ERK1/2), BMAL1 levels (total and nuclear fractions, immunoblot), circadian rhythm (PER2::luciferase real‑time reporting).
• Rescue: Transient overexpression of BMAL1 S42A (non‑phosphorylatable) or CRISPR‑mediated BMAL1 knockout to test dependence.

Expected Outcomes & Falsifiability

If emodin acts as a circadian‑sensitized senolytic, we expect a ≥2‑fold greater reduction in viability of circadian‑disrupted senescent cells versus controls, accompanied by MAPK suppression, BMAL1 stabilization, and SASP attenuation. Failure to observe selective toxicity, or lack of BMAL1 upregulation despite ERK inhibition, would falsify the hypothesis. Conversely, if emodin kills cells irrespective of circadian status, the hypothesis would be narrowed to a general senolytic effect rather than a circadian‑sensitized one.

Implications

Confirming this mechanism would position emodin (or derivatives) as a chronotherapeutic agent that exploits a specific vulnerability of clock‑disturbed senescent cells, offering a strategy to combine senolytic clearance with circadian reinforcement in age‑related pathologies.